The US FDA has accepted the NDA resubmission for CUTX-101, a paediatric therapy for Menkes disease, developed by Zydus Lifesciences’ US arm. The review has been classified as Class I, with a PDUFA target date of 14 January 2026.
Source: Zydus Lifesciences Press Release (NSE Exchange Fillings) | Published on Dec 15, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Zydus Lifesciences (NSE Exchange Filings), the company’s wholly owned US subsidiary, Sentynl Therapeutics, has received acceptance from the US Food and Drug Administration for the resubmission of the New Drug Application for CUTX-101. The investigational drug is intended for the treatment of Menkes disease in paediatric patients. The FDA has classified the filing as a Class I resubmission and assigned a new PDUFA Target Action Date of 14 January 2026.
This regulatory update marks progress for the application after the agency issued a complete response letter in September 2025. The earlier communication focused on observations related to current Good Manufacturing Practice compliance at the manufacturing site and did not raise concerns on clinical data related to safety or efficacy.
Also read: Can Fin Homes Board Declares ₹7 Interim Dividend for FY26
FDA accepts CUTX-101 NDA resubmission as a Class I response
New PDUFA Target Action Date set for 14 January 2026
Earlier FDA observations were limited to manufacturing compliance
No deficiencies cited in safety or efficacy data
CUTX-101 targets Menkes disease in paediatric patients
Also read: Newgen Software Lands ₹56 Crore Worth Contracts In India And Abroad
Sentynl Therapeutics resubmitted the NDA on 14 November 2025 after addressing the issues highlighted in the complete response letter dated 30 September 2025. The FDA review had focused on compliance matters at the manufacturing facility. The agency did not identify gaps in the clinical programme supporting CUTX-101.
Clinical data submitted with the application showed improvement in overall survival among Menkes disease patients who received early treatment. The resubmission process followed standard regulatory timelines and documentation requirements applicable to Class I responses.
CUTX-101 is a copper histidinate formulation developed to address copper deficiency associated with Menkes disease. Menkes disease is a rare X-linked recessive genetic disorder that affects copper transport in the body and primarily impacts male infants. The condition can lead to severe neurological and developmental issues if not managed early.
The estimated prevalence of Menkes disease ranges from approximately one in 34,810 to one in 8,664 live male births, based on genomic database estimates. At present, there is no FDA-approved therapy specifically indicated for this condition.
If approved, CUTX-101 would become the first FDA-approved treatment for Menkes disease. The acceptance of the NDA resubmission allows the regulatory review process to move forward within a defined timeline. The outcome of the FDA review remains subject to completion of the agency’s standard evaluation procedures.
Developments related to rare disease therapies often draw attention within the pharmaceutical sector due to their regulatory complexity and limited treatment options.
Particulars | Details |
Drug Candidate | CUTX-101 (Copper Histidinate) |
Indication | Menkes Disease (Paediatric) |
NDA Resubmission Date | 14 November 2025 |
FDA Classification | Class I Resubmission |
New PDUFA Date | 14 January 2026 |
Previous FDA Observation | Manufacturing cGMP Compliance |
Zydus Lifesciences share price stands at ₹922 per share on the BSE as of 15 December 2025 at 3:30 PM IST, up by 0.8%.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading